Hematology

Biography

Biography: Javad Garavand

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease which its identification owes to the discovery of genetic and epigenetic disorders. Micro-RNAs (miRs) are small, non-coding RNAs that have recently come to the attention of researchers. miRs can affect the expression of hundreds of genes at the DNA and RNA levels. Increasing or decreasing the expression of genes involved in transcription, cell cycle, or apoptosis can lead to cancer. Information related to the impact and application of action of the most important miRs involved in AML was collected from various databases such as Pubmed. In this regard, the design and construction of artificial miRs interfering with genes associated with malignancies can be an effective treatment process with the least complications and the highest efficiency. The malignant cells in some AML subtypes produce new chimeric genes that their protein products are responsible for main part of the disease. Therefore, the use of miRs against these proteins can be a good alternative to chemotherapy drugs that also have a negative effect on normal cells. However, therapeutic use of miRs can be challenging. For example, since each miR can control the expression of several genes simultaneously, great attention must be paid to the specificity of miR for the target protein. On the other hand, transferring miRs to the target cells is another challenge.